Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

Olokizumab came to the fore with three pivotal, phase III core publications in 2022. In a phase III study in which patients with RA whose disease was not adequately controlled with methotrexate (MTX), both OKZ 64 mg every 2 weeks (q2w) and OKZ 64 mg every 4 weeks (q4w) in combination with MTX, established a significant superiority over placebo (PBO) plus MTX in the primary efficacy outcome, American College of Rheumatology 20% (ACR20) response at week 12 (63.6%; 70.4%; 25.9%, respectively, p < 0.0001 for both comparisons) [26]. Additionally, the secondary endpoint of Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) < 3.2 at week 12 was met significantly higher in both OKZ dosage groups compared with the PBO group (38.7%; 33.6%; 3.5%, respectively, p < 0.0001 for both comparisons). The Health Assessment Questionnaire-Disability Index-based physical function also significantly improved in the OKZ groups with least-squares mean changes of 0.54, 0.56, and 0.20, respectively (p < 0.0001 for both comparisons). Safety was consistent with the expected range for this class of agents and the observed immunogenicity was low. Treatment-emergent adverse events (TEAEs), which were reported in 52.9% of patients, were mostly mild to moderate leading to treatment discontinuation in 3.5 and 4.9% of patients on OKZ q4w and q2w compared with 0.7% of patients on PBO. Treatment-emergent serious adverse events (TESAEs) were numerically higher in patients on OKZ q2w and q4w compared with PBO (5.6, 5.6, and 2.8%, respectively), with infections being the most common adverse event, occurring in 2.8% of the patients on OKZ q2w and 1.4% on PBO. Serious infection was not reported in the OKZ q4w group. One TEAE leading to death because of septicemia was reported in OKZ q2w group.

In another phase III study in patients with RA who did not respond to anti-tumor necrosis factor treatments, patients were randomized to OKZ 64 mg q2w, OKZ 64 mg q4w, or PBO plus MTX. All subjects in the PBO group were re-randomized to receive either OKZ 64 mg q2w or OKZ 64 mg q4w at week 16 [27]. The primary endpoint was met with ACR20 response rates of 60.9, 59.6, and 40.6%, respectively (p < 0.01 for both comparisons, at week 12). Additionally, the major secondary efficacy endpoint (DAS28 [CRP] < 3.2) at week 12 was significantly superior in both OKZ arms compared with PBO (p < 0.0001 for OKZ q2w and 0.0035 for OKZ q4w). The safety profile was similar to monoclonal antibodies to the IL-6 receptor. Most of the TEAEs were mild to moderate in severity and were reported in 64.7% of patients with 64.3% in the OKZ q2w group, followed by 59.7% group in the OKZ q4w group (up to week 44, OKZ groups including the period before and after re-randomization) compared with 50.7% in the PBO group (up to week 16) group. Prior to re-randomization, discontinuation because of TEAEs were observed in 4.1% of the OKZ q2w group and 5.4% in the OKZ q4w group compared with 1.4% in the PBO group. Up to week 16, no TESAEs were reported in the PBO group, TESAEs reported in the OKZ groups during the first 16 weeks were 6.5% in the q2w group compared with 1.9% in the q4w group. Furthermore, numerically higher TESAEs were reported in the OKZ 64-mg 2w group up to week 44. No deaths were reported.

In a head-to-head study, patients with RA with an inadequate response to MTX were randomly assigned to receive subcutaneous OKZ at a dose of 64 mg every 2 or 4 weeks, adalimumab (ADA) 40 mg q2w, or PBO while continuing background MTX [28]. At week 12, OKZ resulted in a better efficacy than PBO with respect to the primary efficacy endpoint ACR20 response, 70.3% in OKZ q2w, 71.4% in OKZ q4w, and 44.4% of the patients receiving PBO (p < 0.001 for the superiority of each OKZ dose to PBO) and 66.9% in patients receiving ADA. Of note, OKZ was non-inferior to ADA in both doses in terms of the percentage of patients with an ACR20 response at week 12. The rates of serious adverse events were similar among treatment groups: 4.8% in the OKZ q2w group, 4.2% in the OKZ q4w group, 5.6% in the ADA group, and 4.9% in the PBO group. Infections were the most commonly reported serious adverse events with rates of 1.3, 1.5, 3.5, and 1.6% in the respective groups. Three deaths were reported in the OKZ q2w group followed by two in the OKZ q4w group, and one in each of the ADA and PBO groups because of adverse reactions.

Following phase III core studies, patients were enrolled in an open-label extension study. During the extension period, patients on OKZ 64 mg q2w and q4w continued their medication, patients on ADA and PBO were switched to OKZ 64 mg q2w or q4w [29]. Adverse events were assessed at week 82 and safety monitoring was continued for an additional 20 weeks. In 73.5% of the patients, TEAEs were observed, with infections being the most common adverse event, occurring in 38.5% of the patients. Adverse events leading to treatment discontinuation were infections in 2.5% of the patients followed by laboratory changes such as elevated liver function tests or changes in blood counts in 2% of the patients. Serious adverse events occurred in 11.8% of patients, while serious infections occurred in 4.1%. Deaths were reported in 1.2% of patients, with similar rates in both groups. Throughout the study, the efficacy of OKZ remained consistent, and patients who were switched from PBO or ADA to OKZ treatment groups achieved similar responses to those in the initial OKZ groups and no significant difference was observed in terms of efficacy or safety among the OKZ treatment groups. Olokizumab was well tolerated and had low dropout rates. The main efficacy results of OKZ phase III trials and an overall summary of adverse events and immunogenicity in safety population were shown in Tables 2 and 3.

Sirukumab (SRK) had completed phase III studies and demonstrated similar clinical efficacy compared to TCZ and other IL-6 inhibitors [30‐32]. However, death rates in the SRK arms compared with PBO, especially in the controlled period, led to the decision by the FDA not to grant approval of SRK in August 2017 and the company terminated its development program. In 2021, the long-term extension study of the SIRROUND-D and SIRROUND-T studies enrolling 1820 patients with a median exposure of 2.34 and 2.07 years in the SRK 50-mg q4w group and the 100-mg q2w group, respectively, were published [33]. The efficacy was maintained and the safety profile did not change from the reported profile in SIRROUND-D and SIRROUND-T studies. Throughout the studies, 32 deaths were reported, 27 during the primary study periods and five in the long-term extension. The death rates were 0.5/100 year (50 mg q4w) and 0.4/100 year (100 mg q2w) mainly due to serious infections and major adverse cardiovascular events. As mentioned in the discussion of the study, mortality rates were similar with long-term TCZ and SAR data [34, 35]

Clazakizumab (BMS945429; ALD518) is another monoclonal humanized antibody that binds to circulating IL-6 cytokine and blocks both classic and trans-signaling [36]. Although it was more potent than TCZ in in-vitro assays, and showed efficacy in phase II trials, the company stopped further development in RA and phase III trials have not been performed [37, 38]. Additionally, MEDI5117, a fully human monoclonal antibody targeting IL-6 has been developed from the progenitor anti-IL-6 human monoclonal antibody CAT6001 by variable domain engineering to achieve a higher affinity and an improved half-life; however, a phase I trial in patients with RA has been terminated because of difficulties with patient recruitment (ClinicalTrials.gov identifier NCT01559103) [39, 40]. Another recombinant humanized monoclonal antibody (gerilimzumab, GB3224) against IL-6 has been evaluated in healthy adults in a phase I study. A single-dose subcutaneous administration of gerilimzumab was well tolerated with desirable pharmacokinetics and a low immunogenicity [41]. However, a phase II study evaluating further the safety and efficacy profile in RA was not started because of a sponsor’s decision (ClinicalTrials.gov identifier: NCT02795299) [42].

Following the successful worldwide use of IL-6R inhibitors TCZ and SAR, results for a new IL-6R inhibitor, levilimab (LVL), were shown at the European League Against Rheumatism (EULAR) Congress 2021. Twenty-four-week results of efficacy and safety of a phase III, double-blind, PBO-controlled, randomized clinical study (SOLAR) have been mainly reported [43]. The study aimed to confirm the superiority of LVL (162 mg, subcutaneously, once weekly) plus MTX over PBO plus MTX in patients with RA resistant to treatment with MTX, in terms of ACR20 at week 12 and low disease activity at week 24. Levilimab plus MTX achieved both primary outcome points (71 vs 40% for ACR20; p = 0.0003 and 52 vs 6% for low disease activity; p < 0.0001) at the end of the study. The spectrum of adverse events observed in this period were similar to other IL-6R inhibitors without any new safety signals.

At EULAR 2022, 1-year results of the open-label period of the SOLAR study have been presented [44]. In the open-label period, patients who achieved DAS28-CRP ≤ 2.6 at week 24, were switched to a maintenance dose of LVL, every 2 weeks plus MTX. Patients with a DAS28-CRP score over 2.6 continued the weekly regimen of LVL+MTX. In the q2w LVL group, the ACR70 response, DAS28-CRP < 2.6, and ACR/EULAR2011 remission rates were 55.6, 85.2, and 25.9%, respectively at week 24. After 1 year, the rates were 63.0, 77.8, and 44.4%, respectively. The rates did not differ significantly in terms of the ACR70 response and DAS28-CRP remission rates and even further increased with respect to ACR/EULAR 2011 remission criteria after 52 weeks. These findings suggested the possibility of switching to a maintenance dose of LVL q2w in patients with RA who achieved remission.

Moreover, patients who could not achieve DAS28-CRP remission at week 24 and had a continued weekly regimen of LVL+MTX reached remission rates of 46.7% of DAS28-CRP and 10.7% of ACR/EULAR 2011 remission and 36% ACR70 response after 1 year, confirming the maintained efficacy of LVL+MTX in patients with active RA resistant to treatment with MTX. The safety analysis was again similar to other IL-6R inhibitors. No deaths occurred. Subsequently, LVL has been approved in Russia, but no results from real-life clinical practice have been reported so far [45]. The main efficacy results and most common adverse events in LVL phase III trials are shown in Table 4.

ALX-0061 (vobarilizumab) is a bispecific anti-IL-6R nanobody designed to have an extended half-life in vivo by targeting human serum albumin, in combination with strong target binding using a single anti-IL-6R building block in order to inhibit the proinflammatory activities. It appears to modulate the IL-6 trans-signaling pathway in addition to the classical mIL-6R-dependent pathway [46]. Because of the small size, these nanobodies have low in-vivo toxicity and immunogenicity and can be rapidly eliminated from the body by the kidneys [47, 48]. Compared with TCZ, ALX0061 has a 2400-fold higher affinity for the sIL-6 receptor and a 17-fold higher affinity for mIL-6R. In a phase I/II study, ACR 20 response rates reached up to 84% and DAS28 remission rates up to 58% [49]. In a phase IIb monotherapy study conducted head-to-head with TCZ in 251 patients with RA, ALX0061 demonstrated comparable or superior efficacy in primary and secondary efficacy endpoints [50]. In an open-label extension study assessing the long-term efficacy and safety of ALX-0061 in RA over 104 weeks, ACR20, ACR50, and ACR70 rates reached 97, 84, and 72%, respectively [51].

The successful results of TCZ in many inflammatory conditions have brought biosimilars to the agenda after expiration of its patent period. In this regard, BAT1806/BIIB800 has been approved for use in RA by China’s National Medical Products Administration and has been filed applied for approval to both at the FDA and the European Medicines Agency [52].

The results of the phase III study BAT1806/BIIB800 in patients with RA with moderate-to-severe disease activity and irresponsive to MTX were published at the EULAR Congress in 2022 [53]. With a randomization of 2:1:1, patients were divided into three groups: (1) those who received BAT1806/BIIB800 for 48 weeks; (2) those who received TCZ for 48 weeks; or (3) those who received TCZ for 24 weeks followed by BAT1806/BIIB800 for the next 24 weeks. The administrations were performed at a dose of 8 mg/kg every 4 weeks. The primary endpoints of the study were the ACR responses at week 12 and week 24. ACR20 rates in BAT1806/BIIB800 and TCZ groups were 68.97 versus 64.82% at week 12 and 69.89 versus 67.94% at week 24, respectively. The confidence intervals for the estimated differences were within the pre-defined equivalence margins. Compared to reference TCZ, BAT1806/BIIB800 exhibited comparable efficacy at both the 12th and 24th weeks of the study. Moreover, at the 24th week, the pharmacokinetic profiles, safety, and immunogenicity were similar.

The results from week 24 to week 48 were published at the American College of Rheumatology Convergence 2022 [54]. At week 48, the ACR20 rates in groups 1, 2, and 3 were 92.9, 92.2, and 93.5%, respectively. The ACR20/50/70 responses and mean changes in DAS28-erythrocyte sedimentation rate and DAS28-CRP scores from baseline were similar between the groups. No deaths occurred during this period. Safety, immunogenicity, and pharmacokinetic profiles were comparable among the three groups, and no additional safety or immunogenicity concerns were observed in the group that switched from TCZ to BAT1806. Other TCZ biosimilars such as HS628, QX003S, and MSB11456 have also been developed and entered into a clinical trial program [55‐59].